Jonathan Zalevsky

Jonathan Zalevsky

Company: Nektar Therapeutics

Job title: Chief R&D Officer


NKTR-358, a Modified IL-2 Pathway Agonist for Selective Expansion of Tregs in vivo 1:30 pm

Discussing the design of NKTR-358 using polymer chemistry Exploring NKTR-358’s mechanism of action and preclinical development Presenting Clinical highlights demonstrating Treg specificity and an optimal pharmacology profile for the treatment of autoimmune diseasesRead more

day: Day One | Track B | Morning

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.